Biocytogen: Innovative Models to Empower Antibody Discovery
Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ Mouse), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with top pharmaceutical and biotechnology companies worldwide. Together, we discover innovative medicines for a better, healthier world.
At Biocytogen, we have over 1200 genetically modified strains of BioMice that have assisted many of the top pharmaceutical companies with their R&D projects.
- Advance life sciences with high-quality and customized models to push the boundary of utilization of humanized target models in biomedical research
- Develop technological platforms to accelerate next-generation drug discovery and development
- Empower scientists in drug discovery by providing the necessary expertise to eliminate bottlenecks in research
- Be a global leader in providing seamless preclinical services to our clients
Biocytogen merges with Eucure Biopharma, aiming to create innovative antibody drugs to improve human health worldwide.
Anti-CTLA-4 and OX40 antibodies YH001 and YH002 approved for clinical trials in China
Anti-OX40 antibody YH002 was approved for clinical trials in the United States
Anti-CTLA-4 antibody YH001 was approved for clinical trials in the United States
Developed RenMab Mouse, a fully human antibody mouse model; Closed D-round funding in July
Received C-round funding from SDIC Venture Capital, 3E Bioventures, Cowin Capital Group and Oriza Holdings
Boston and Shanghai sites opened for business
Haimen Animal Center began operations; AAALAC accreditation earned; Antibody Discovery Service Platform established; B-NDG™ and a comprehensive variety of humanized immune checkpoint mice were supplied to clients
Established preclinical services platform; Raised B-round funding from SDIC Venture Capital and BioVeda China Fund
Developed B-NDG™ mice (highly immune deficient) and B-hPD-1, the first humanized immune-checkpoint mouse model
Developed ESC/HR-based gene editing technology platform and delivered gene editing services to our first customer.
Beijng Biocytogen Co., Ltd (Headquarters) established